MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Accounts Receivables 2011-2026 | SYNH
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 729 M | - | 211 M | 158 M | 130 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 M | 130 M | 307 M |
Quarterly Accounts Receivables Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 782 M | 769 M | 776 M | 724 M | 729 M | 729 M | 729 M | 729 M | 643 M | 643 M | 643 M | 188 M | 211 M | 179 M | 190 M | 211 M | 158 M | 158 M | 158 M | 158 M | 130 M | 130 M | 130 M | 130 M | 130 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 782 M | 130 M | 406 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
42.6 M | $ 17.82 | - | $ 950 M |  USA |
 |
Agilent Technologies
A
|
1.17 B | $ 114.84 | - | $ 34.9 B | USA |
 |
Co-Diagnostics
CODX
|
190 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 168.22 | - | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 24.73 | - | $ 687 M | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 192.12 | - | $ 137 B | USA |
 |
DexCom
DXCM
|
1.22 B | $ 63.21 | - | $ 24.7 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
138 M | $ 89.66 | - | $ 11.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 109.62 | - | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
735 M | $ 127.74 | - | $ 20.3 B | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 274.46 | - | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 75.89 | - | $ 5.12 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.3 | - | $ 175 M |  China |
 |
Medpace Holdings
MEDP
|
402 M | $ 496.0 | - | $ 14.3 B | USA |
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.67 | - | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.85 K | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
159 M | $ 8.02 | - | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.56 | - | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 17.33 | - | $ 388 M | USA |
 |
Natera
NTRA
|
244 M | $ 204.87 | - | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.42 | - | $ 426 M | USA |
 |
Precipio
PRPO
|
1.98 M | $ 25.98 | 2.28 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 6.58 | - | $ 390 M | USA |
 |
Sotera Health Company
SHC
|
139 M | $ 14.87 | - | $ 4.22 B | USA |
 |
Soleno Therapeutics
SLNO
|
28.2 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
16.5 M | $ 1.76 | - | $ 116 M | USA |
|
Biodesix
BDSX
|
8.6 M | $ 15.36 | - | $ 1.99 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.9 B | $ 488.19 | - | $ 184 B | USA |
 |
VolitionRx Limited
VNRX
|
318 K | $ 0.17 | - | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
829 M | $ 304.09 | - | $ 18.1 B | USA |
 |
Exagen
XGN
|
10.9 M | $ 3.08 | - | $ 66.4 M | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
173 K | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
5.2 M | $ 1.15 | - | $ 6.26 M | USA |